Aetion, the global leader in real-world evidence (RWE) technology and analytics, has been named a Leader in CB Insights’ Synthetic Patient Data Market Analysis. Aetion received a 9.8/10 score in the Execution, Strength, and Positioning (ESP) matrix, the highest among the 15 vendors featured. This recognition highlights Aetion’s ability to deliver scientifically rigorous solutions that meet the complex needs of healthcare and life sciences organizations. Read CB Insights’ full analysis of the synthetic patient data market here.
“Since Aetion first expanded into synthetic patient data with the acquisition of the pioneering startup Replica Analytics in 2022, we have advanced the use of synthetic patient data as a vital tool for clinical research, treatment evaluation, and privacy risk assessment by enabling robust, decision-grade evidence generation,” said Kevin Riley, President of Aetion. “We wrote the book on synthetic data in healthcare and this recognition by CB Insights highlights the scientific foundation of Aetion’s platform and its ability to address the complex analytical needs of our clients.”
The CB Insights ESP matrix identifies the most established service providers in the market, with Leaders distinguished by their ability to address diverse customer needs. Synthetic patient data, as defined by CB Insights, offers a powerful solution to address challenges in privacy, security, and data access, enabling innovation in clinical trials, predictive modeling, and healthcare technology development.
Aetion’s platform was recognized for its excellence in:
- Scientific Rigor: Applying rigorous scientific methods to create synthetic data that mirrors the characteristics and integrity of the original datasets, ensuring high-quality, reproducible insights for healthcare research and decision-making.
- Versatility: Enabling robust application across diverse therapeutic areas and data sources, with utility extending beyond real-world evidence studies to include predictive modeling, ethical access to sensitive data for internal decision-making, and secure frameworks for external data sharing.
- Transparency and Objectivity: Building confidence among clients through rigorous methodologies and clear documentation of the generation, validation, and application of synthetic data.
Driving Impact Across Healthcare
Aetion’s solutions have demonstrated the ability to drive meaningful outcomes for healthcare organizations:
- Accelerated Research: Synthetic data enables faster study feasibility assessments, predictive modeling, and hypothesis generation, reducing time-to-insight for clinical trials and market access strategies.
- Cost Efficiency: Synthetic data enhances the value of existing data sources by addressing gaps, improving representation, and de-biasing datasets. This allows organizations to generate more robust insights without relying solely on additional external data acquisitions.
- Fostering Innovation and Collaboration: Synthetic data supports internal innovation by providing realistic datasets for software development, building ETL (Extract, Transform, Load) pipelines, and hypothesis testing. It also facilitates secure, privacy-preserving data sharing across organizations, enabling external partnerships and collaborative research while maintaining compliance with privacy regulations.
- Improved Evidence Generation: Synthetic data replicates real-world data characteristics, supporting advanced modeling for treatment effectiveness, safety profiling, and comparative analyses critical to regulatory and market access decisions.
Synthetic patient data is transforming healthcare research by enabling compliant, privacy-secured analyses that preserve the utility of real-world data. Aetion’s platform empowers organizations with the tools they need to generate actionable insights and improve outcomes while meeting stringent regulatory standards.
